EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 3-Nov-2026 16:16 ET (3-Nov-2026 21:16 GMT/UTC)

Model reveals strategies to modify the tumor microenvironment and improve cancer therapy

Mass General Brigham
Peer-Reviewed Publication

The model incorporates key features of the tumor microenvironment, including abnormal blood vessels, elevated interstitial fluid pressure, immune cell activity, drug transport and tumor-draining lymph nodes.

Journal: Journal for ImmunoTherapy of Cancer
Funder: European Research Council, National Foundation for Cancer Research, Jane's Trust, Niles Albright Research Foundation, Harvard Ludwig Cancer Center

Focusing on the ‘obesity paradox’ to improve cancer treatment success

McGill University
Peer-Reviewed Publication

To the surprise of researchers, certain diets often considered “unhealthy” or “fattening” were associated with better responses to a type of cancer immunotherapy.

"There is a synergistic relationship between the bacteria that reside in our GI tract, and the food we eat,” said Daniela Quail, Associate Professor in the Department of Physiology and Principal Investigator at the Rosalind & Morris Goodman Cancer Institute.

Journal: Nature

Cell paper identifies subclusters driving cancer-induced cachexia

University of Oklahoma
Peer-Reviewed Publication

Research published today in Cell identifies three small subclusters of cells driving pancreatic cancer-induced cachexia, a muscle-wasting and fat-loss condition that makes patients less tolerant of cancer treatment. The study, led by the University of Oklahoma, holds significant promise for the development of therapeutics to target these subclusters.

Journal: Cell

Anti-cancer molecules show promise in the fight against malaria

Fundação de Amparo à Pesquisa do Estado de São Paulo
Peer-Reviewed Publication

In vitro tests conducted at the University of São Paulo suggest that the compounds eliminate the parasite during both the symptomatic phase and the stage at which it infects the mosquito vector.

Journal: ACS Omega
Funder: Fundação de Amparo à Pesquisa do Estado de São Paulo

Distinct gut microbiome patterns found in 5 cancer groups and in early-onset cancers

Mayo Clinic
Peer-Reviewed Publication

Mayo Clinic researchers discovered distinct gut microbiome patterns in adults 50 or younger with colorectal and breast cancers compared with those diagnosed later in life — one of several findings from an analysis of stool samples from 1,364 patients with cancer across cancer types, stages and treatments.

Journal: Cell
Funder: National Institutes of Health, Valhalla Foundation, Maxine and Jack Zarrow Family Foundation, Mayo Clinic Microbiome Program, Mayo Clinic Center for Individualized Medicine

Grant awarded to BU-led team targeting early lung cancer detection

Boston University School of Medicine
Grant and Award Announcement

(Boston)—Joshua D. Campbell, PhD, associate professor of medicine at Boston University Chobanian & Avedisian School of Medicine, has been awarded a five-year, $3.4M U01 grant from the NIH’s National Cancer Institute Human Tumor Atlas Network (HTAN) for the project, “Integrative biomarkers to improve clinical management of lung ground glass nodules.” Campbell and colleagues led the establishment of the Lung Pre-Cancer Atlas, a cellular map of the earliest stages of lung cancer during the first round of HTAN funding (Phase I - A. Spira). This Phase II award will allow the team to begin to translate the Lung Pre-Cancer Atlas efforts into clinically useful biomarkers.

Bile genome sequencing may accelerate diagnosis of malignant biliary strictures

First Hospital of Jilin University
Peer-Reviewed Publication

Ultra-low-pass whole-genome sequencing of bile cell-free DNA may improve the evaluation of biliary strictures, particularly when initial pathology is inconclusive. In 95 patients, the approach detected tumour DNA with 96% specificity in initially indeterminate cases and anticipated conventional diagnosis by a median of 38 days. Copy-number profiles also helped distinguish cholangiocarcinoma from pancreatic ductal adenocarcinoma, while integration with targeted mutation burden identified a subgroup with significantly poorer overall survival, supporting prospective multicentre and independent validation.

Journal: eGastroenterology

Post-translational modifications of KRAS: from molecular regulation to therapeutic targeting

ELSP
Peer-Reviewed Publication

A recent review highlights that post-translational modifications add a dynamic regulatory layer to KRAS beyond canonical GDP/GTP cycling, controlling membrane localization and trafficking, nucleotide exchange, effector engagement, protein stability, and degradation. Targeting PTM enzymes and modification-dependent regulatory networks may provide new therapeutic opportunities and strategies to overcome resistance in KRAS-driven cancers.

Journal: Advanced Cancer Research

CCT2 drives HNSCC progression and cisplatin chemoresistance

Compuscript Ltd
Peer-Reviewed Publication

Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy characterized by poor survival due to rapid progression, metastasis, and cisplatin resistance. The chaperonin containing TCP-1 subunit 2 (CCT2), a subunit of the chaperonin-containing TCP-1 (CCT) complex, has been previously implicated in several cancers, but its specific role and contribution to chemoresistance in HNSCC remain elusive.

Journal: Genes & Diseases
Funder: National Natural Science Foundation of China, Dongguan Science and Technology of Social Development Program (Guangdong, China), Guangdong Basic and Applied Basic Research Foundation (China), Clinical plus Basic Innovation Project of Guangdong Medical University (China), Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University (China), Basic and Applied Basic Research Foundation of Guangzhou City, Guangdong, China

Single-cell atlas identifies DLL3 as a therapeutic target in neuroendocrine cervical cancer

Compuscript Ltd
Peer-Reviewed Publication

Neuroendocrine carcinoma of the cervix (NECC) is a rare but highly aggressive subtype of cervical cancer characterized by rapid progression, early metastasis, and poor survival. Current treatment strategies are largely adapted from other neuroendocrine malignancies and conventional cervical cancers, yet clinical outcomes remain unsatisfactory. Although genomic studies have begun to uncover recurrent genetic alterations in NECC, the tumor immune microenvironment (TIME) and cellular interactions driving disease progression remain poorly understood, limiting the development of effective targeted therapies.

Journal: Genes & Diseases
Funder: National Natural Science Foundation of China, Medical Innovation Research of Shanghai Science and Technology (China), Shanghai Hospital Development Center (China), Medical Innovation Research of Shanghai Science and Technology (China), The Eastern Talent Plan Project (China), The Simulated RCT study of Shanghai Shenkang Hospital Development Center (China), Huangpu Youth Talent Project

37
38
39
40
41